CEACAM5 and non-small cell lung carcinoma: In the dose-expansion, phase Ib portion of the same trial involving 92 patients with NSCLC and high or moderate CEACAM5 expression receiving tusamitamab ravtansine 100 mg/m2 (maximum tolerated dose), keratopathy/keratitis was the most common AE (38% of patients, grade ≥3 in 10.9%).52 Dose modification due to ocular AEs was required in 27.2% of patients.